The purpose of the American Academy of Pediatrics (AAP) Quality Networks Improving Immunization Rates for Adolescents (IIRA2) Change Package is to present a directory of evidence, best practices, and promising ideas that adolescent-focused medical practices can use as they work to improve immunization-related care.
The tools and resources contained in the IIRA2 change package are meant to be adapted or adopted in your healthcare setting to improve immunization processes. Many of the resources were initially developed and/or used in previous AAP Quality Network immunization projects to systematize and improve immunization care.
Several included resources have been tested in contexts outside of the AAP Quality Networks and were recommended for use by subject matter experts. Consequently, some clinical resources may reflect office processes and policies that differ from that of your own care team or practice and will require tailoring to meet the needs of your specific patient population and care team environment.
Immunization Landscape (& Pandemic-Related Vaccination Trends)
Routine immunizations reduce community transmission of infections and induce long-term immunity, making vaccines a cornerstone of childhood and adolescent wellness in the United States. Vaccinating children and adolescents according to the U.S. Advisory Committee on Immunization Practices (ACIP) recommended schedule offers communicable disease protection not only for the individual, but also for the community.
Adolescent immunization platforms were established in 2016 and 2017. These platforms emphasized the importance of maintaining vaccination coverage during two highlighted time-periods: early adolescence (age 11- to 12) and age 16. From 2016 until the onset of the COVID-19 pandemic in March 2020, adolescent immunization coverage rates were steady or rising (see Table 1 below).
|
Vaccination |
Reported adolescent vaccination |
Reported adolescent vaccination coverage rates in 2017 (ages 13-17) |
Reported adolescent vaccination coverage rates in 2019 (ages 13-17) |
Reported |
|
Hepatitis A (HepA) [2 doses] |
|
|
77.1% |
82.1% |
|
Hepatitis B (HepB) [3 doses] |
91.4% |
91.9% |
91.6% |
92.6% |
|
Human papillomavirus |
60.4%; 43.4% |
65.5%; 48.6% |
71.5%; 54.2% |
75.1%; 58.6% |
|
Influenza |
48.8% (2016/17 season) |
47.3% (2017/18 season) |
52.1% (2018/19 season) |
53.3% (2019/20 season) |
|
Meningococcal |
82.2%; 39.1% |
85.1%; 44.3% |
88.9%; 53.7% |
89.3%; 54.4% |
|
Meningococcal |
|
|
21.8% |
28.4% |
|
Measles, mumps, and |
90.9% |
92.1% |
91.9% |
92.4% |
|
Tetanus, diphtheria, acellular pertussis (Tdap) [≥1 dose] |
88.0% |
88.7% |
90.2% |
90.1% |
|
Varicella (VAR) [hx. of disease or recipient of |
87.8% |
90.1% |
91.5% |
92.6% |
Last Updated
02/06/2023
Source
American Academy of Pediatrics